<DOC>
	<DOCNO>NCT01881529</DOCNO>
	<brief_summary>To treat patient scleroderma block expression LOXL2 . The investigator first need confirm ( observation ) LOXL2 overexpressed disease .</brief_summary>
	<brief_title>A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 ( LOXL2 ) Present Subjects With Scleroderma</brief_title>
	<detailed_description>Scleroderma chronic skin-hardening disease . There two type scleroderma . The first type call limit cutaneous scleroderma , disrupt blood flow cause skin discoloration sometimes patient experience high blood pressure artery . The second type call diffuse cutaneous scleroderma much aggressive , affect large area skin cause organ damage . This study determine disease associate elevated expression LOXL2 level tissue sample patient .</detailed_description>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<mesh_term>Scleroderma , Limited</mesh_term>
	<criteria>Over 18 year age Documented diagnosis scleroderma Willing able provide write informed consent Use experimental therapy within 28 day prior Screening . Aspirin use &gt; 81 mg daily within 1 week prior Screening . Any lab abnormality concurrent medical condition , opinion investigator would make patient ineligible study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>limited scleroderma</keyword>
	<keyword>diffuse scleroderma</keyword>
	<keyword>Sclerosis</keyword>
	<keyword>Progressive</keyword>
	<keyword>Limited</keyword>
</DOC>